Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
Published: Mar 01, 2018
SOUTH SAN FRANCISCO, Calif., March 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib data from its FIT Phase 3 extension study (FIT3) in patients with chronic immune thrombocytopenia (ITP) and preliminary data from its SOAR Phase 2 clinical study in patients with warm antibody autoimmune hemolytic anemia (AIHA) will be presented at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America on March 8 - 10, 2018 in San Diego, CA.
Fostamatinib disodium is an oral investigational drug candidate designed to inhibit spleen tyrosine kinase (SYK), a key signaling component of the body's immune process that leads to platelet destruction in ITP and red blood cell destruction in AIHA. SYK inhibition by fostamatinib can affect antibody-mediated platelet destruction, an underlying cause of ITP. Fostamatinib may also impair antibody-mediated red blood cell destruction in AIHA, a rare disease for which there are no approved therapies.
Fostamatinib Oral Presentation
Fostamatinib Poster Presentation
About Rigel (www.rigel.com)
This press release contains "forward-looking" statements, including statements related to Rigel's belief that fostamatinib may benefit patients with AIHA and the timing and nature of results of Rigel's clinical trials. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "goal," "expects," "can," "may" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-Q for the quarter ended September 30, 2017. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.
Contact: Raul Rodriguez
Media Contact: Jessica L. Daitch, Syneos Health
View original content with multimedia:http://www.prnewswire.com/news-releases/rigel-announces-two-fostamatinib-presentations-at-the-4th-biennial-summit-of-the-thrombosis--hemostasis-societies-of-north-america-300606277.html
SOURCE Rigel Pharmaceuticals, Inc.
Company Codes: NASDAQ-NMS:RIGL